home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 10/25/21

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies

FLORHAM PARK, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced it is collaborating with BBK Worldwi...
CLRB - Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer

FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the completion of the part A portion of a sa...

CLRB - Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will p...

CLRB - Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia

FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National ...
CLRB - Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131

Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131) Agreement adds second manufacturer and expands Cellectar’s current supply capabilities FLORHAM PARK, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc.&#...

CLRB - Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update

FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the second quarter ende...

CLRB - Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.

FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that it has expanded its ongoing collaboratio...
CLRB - Cellectar Biosciences inks collaboration agreement with South Korea's LegoChemBio

subjob/iStock via Getty Images Cellectar Biosciences ("CLRB") has signed an agreement with South Korea's LegoChemBio to collaborate on the development and commercialization of first-in-class phospholipid drug conjugates ("PDCs"). Under the deal, both companies have the option to jointly devel...

CLRB - Cellectar inks development and commercialization agreement with LegoChemBio

Cellectar Biosciences (CLRB) has entered into a development and commercialization collaboration with South Korea-based biotechnology company LegoChemBio for the development and commercialization of novel first-in-class phospholipid drug conjugates ((PDCs)).Shares up nearly...

CLRB - Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)

FLORHAM PARK, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that it has entered into a development and co...
Previous 10 Next 10